Effective for dates of service beginning July 1, 2023, certain medications will no longer be offered as part of Tufts Health Plan’s office-administered medical drug/white bagging program.
The drugs identified below will be removed from our Office-Administered Medical Drugs list for Tufts Health Direct, as well as for Tufts Health Plan Commercial and Tufts Medicare Preferred, and will no longer be available through CVS Caremark:
Aranesp | Arzerra |
Avastin | Epogen |
Gel-One | GenVisc 850 |
Hyalgan | Leukine |
Lucentis | Monovisc |
Mozobil | Neulasta |
Neupogen | Octreotide |
Orthovisc | Procrit |
Sandostatin | Supartz |
Synvisc | Synvisc-One |
Vantas | Zarxio |
Providers can continue to buy and bill these medications once prior authorization has been obtained. (You can request prior authorization in a number of ways, but we recommend submitting requests electronically through PromptPA for its ease of use and quick turnaround times.)
In addition, some of the medications may be available under Tufts Health Plan’s Pharmacy benefit. Please refer to the relevant plan’s online formulary to confirm Pharmacy coverage of drug.
Audrey Kleinberg,
Director, Provider Relations & Communications
Annmarie Dadoly,
Senior Manager, Provider Communications
Joseph O’Riordan, Jesse Salvato, Stephen Wong,
Writers
Kristin Edmonston,
Production Coordinator
Kristina Cicelova,
Graphic Designer